Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Grifols SA    GRF   ES0171996087

GRIFOLS SA (GRF)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Bolsa De Madrid
10/10/2017 10/11/2017 10/12/2017 10/13/2017 10/16/2017 Date
23.95(c) 24.22(c) 24.25(c) 24.13(c) 24.24(c) Last
646 960 599 023 416 206 350 428 351 030 Volume
-1.03% +1.13% +0.12% -0.49% +0.46% Change
More quotes
Financials (€)
Sales 2017 4 339 M
EBIT 2017 1 106 M
Net income 2017 635 M
Debt 2017 5 596 M
Yield 2017 1,47%
Sales 2018 4 528 M
EBIT 2018 1 207 M
Net income 2018 723 M
Debt 2018 5 201 M
Yield 2018 1,68%
P/E ratio 2017 26,19
P/E ratio 2018 22,90
EV / Sales2017 4,76x
EV / Sales2018 4,47x
Capitalization 15 061 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments: ... 
Sector
Pharmaceuticals
Calendar
11/02Earnings Release
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
10/09 THE LATEST : Barcelona mayor says all sides must de-escalate
09/26 GRIFOLS : FDA approves Grifols Prolastin-C Liquid for the treatment of alpha-1 a..
09/25 GRIFOLS : research lines in Alzheimer's move forward with both treatment and pre..
09/23 GRIFOLS : Engagement
09/21 GRIFOLS : research lines in Alzheimer's move forward with both treatment and pre..
09/19 GRIFOLS : Select American Red Cross Blood Donations Screened for Babesia Parasit..
09/03 GRIFOLS : Value Based Pharmaceutical Pricing – Is it Affordable?
09/02 GRIFOLS : Federal Contracts Awarded by Federal Agencies in Kentucky (Sept. 2)
08/31 GRIFOLS : MILITARY $42,083 Federal Contract Awarded to Gen-Probe
08/23 GRIFOLS : Supervisor Solis Commends LA BioStart Graduates at Cal State LA Event
More news
Sector news : Biopharmaceuticals
02:48aDJDaimler Charts Leaner Approach -- WSJ
02:46aDJASTRAZENECA : FDA Accepts Imfinzi Supplemental Biologics License Application; Gr..
10/16DJALLERGAN : Loses Patent Fight in Federal Court
10/16DJDaimler Reshapes Company to Meet Challenges of Changing Industry -- Update
10/16 Miners provide foundation for FTSE while ConvaTec plummets
More sector news : Biopharmaceuticals
Latest Tweets
10/16Aradigm (ARDM) Shares March Higher, Can It Continue? -  
10/14Aradigm Corporation $ARDM Earns Daily News Sentiment Rating of 0.13  
10/12Global Intravenous Immunoglobulin (IVIg) Strategic Business Report 2017-2024 .. 
10/12Global Intravenous Immunoglobulin (IVIg) Strategic Business Report 2017-2024 .. 
10/12Global Intravenous Immunoglobulin (IVIg) Strategic Business Report 2017-2024 .. 
More tweets
Qtime:73
News from SeekingAlpha
09/22 ARADIGM : Hidden Binary Event Or Russian Roulette (With The FDA Spinning The Cha..
09/11 Big Pharma Duet Greets REIT Atop 'Safer' Dividend Healthcare Pack For Gains I..
08/10 HealthSouth Invades Big Pharma Duet To Place Atop 'Safer' Dividend Healthcare..
07/31 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 31, 2017
07/28 Grifols S.A. reports 1H results
Chart GRIFOLS SA
Duration : Period :
Grifols SA Technical Analysis Chart | GRF | ES0171996087 | 4-Traders
Technical analysis trends GRIFOLS SA
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 24,6 €
Spread / Average Target 1,6%
EPS Revisions
Managers
NameTitle
Raimon Grifols Roura Joint Chief Executive Officer & Director
Victor Grifols Deu Joint Chief Executive Officer & Executive Director
Víctor Grifols Roura Non-Executive Chairman
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Vicente Blanquer Torre Vice President-Quality, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS SA27.81%17 727
BIOGEN29.20%71 388
CSL LIMITED37.10%48 715
ALEXION PHARMACEUTICALS14.92%31 382
BIOMARIN PHARMACEUTICAL14.82%16 672
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%6 830